autologous irradiated tumor cells

Autologous irradiated tumor cells represent a personalized cancer immunotherapy platform where a patient's own malignant cells are harvested, inactivated via irradiation to prevent proliferation while maintaining their antigenic profile, and then re-administered to the patient as a vaccine. This approach aims to present the full repertoire of patient-specific tumor-associated antigens (TAAs) and neoantigens to the immune system, addressing tumor heterogeneity. To enhance immunogenicity, these cells are frequently co-administered with adjuvants such as Bacillus Calmette-Guèrin (BCG), granulocyte-macrophage colony-stimulating factor (GM-CSF), or cytokines like Interleukin-2 (IL-2). The platform has been investigated across various solid tumors, including renal cell carcinoma, glioblastoma, and head and neck squamous cell carcinoma, often showing the ability to induce specific cytotoxic T-lymphocyte responses and delayed-type hypersensitivity reactions.

Other names

autologous tumor cell vaccineirradiated autologous tumor cellsAITCautologous tumor-derived bodies